MA47522B1 - Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation - Google Patents
Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisationInfo
- Publication number
- MA47522B1 MA47522B1 MA47522A MA47522A MA47522B1 MA 47522 B1 MA47522 B1 MA 47522B1 MA 47522 A MA47522 A MA 47522A MA 47522 A MA47522 A MA 47522A MA 47522 B1 MA47522 B1 MA 47522B1
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- vectors
- immunodeficiency virus
- human immunodeficiency
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 2
- 230000036039 immunity Effects 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des protéines synthétiques d'enveloppe du vih, des vecteurs et des compositions de celles-ci, ainsi que des procédés d'induction d'une immunité protectrice contre une infection par le virus de l'immunodéficience humaine (vih). Des vecteurs d'expression viraux codant pour les protéines synthétiques de l'enveloppe du vih peuvent être utilisés dans des vaccins pour fournir une immunité protectrice améliorée contre le vih.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15200138 | 2015-12-15 | ||
EP16194124 | 2016-10-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47522A MA47522A (fr) | 2021-05-05 |
MA47522B1 true MA47522B1 (fr) | 2021-11-30 |
Family
ID=57737697
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44059A MA44059B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation |
MA47522A MA47522B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
MA055825A MA55825A (fr) | 2015-12-15 | 2016-12-15 | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44059A MA44059B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055825A MA55825A (fr) | 2015-12-15 | 2016-12-15 | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
Country Status (29)
Country | Link |
---|---|
US (3) | US10369214B2 (fr) |
EP (3) | EP3964569A1 (fr) |
JP (2) | JP6510149B2 (fr) |
KR (1) | KR20180086207A (fr) |
CN (2) | CN108368157B (fr) |
AU (2) | AU2016369326B2 (fr) |
BR (1) | BR112018011122A2 (fr) |
CA (1) | CA3008542C (fr) |
CY (2) | CY1122705T1 (fr) |
DK (2) | DK3390430T3 (fr) |
EA (1) | EA038974B1 (fr) |
ES (2) | ES2898271T3 (fr) |
HR (2) | HRP20211566T1 (fr) |
HU (2) | HUE045993T2 (fr) |
IL (1) | IL259942B2 (fr) |
LT (2) | LT3584252T (fr) |
MA (3) | MA44059B1 (fr) |
MD (2) | MD3390430T2 (fr) |
ME (1) | ME03545B (fr) |
MX (2) | MX2018007198A (fr) |
PH (1) | PH12018501047A1 (fr) |
PL (2) | PL3390430T3 (fr) |
PT (1) | PT3390430T (fr) |
RS (2) | RS62360B1 (fr) |
SG (2) | SG10202109457RA (fr) |
SI (2) | SI3584252T1 (fr) |
TW (2) | TWI792091B (fr) |
WO (1) | WO2017102929A1 (fr) |
ZA (1) | ZA201803978B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2017009846A0 (en) | 2014-09-26 | 2017-03-31 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
EP3031923A1 (fr) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux |
MD3390430T2 (ro) | 2015-12-15 | 2019-12-31 | Janssen Vaccines & Prevention Bv | Antigenele virusului imunodeficienței umane, vectori, compoziții și metode de utilizare ale acestora |
MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
EA201990715A1 (ru) | 2016-09-15 | 2019-08-30 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизирующие тример мутации белка оболочки hiv |
JP7272965B2 (ja) | 2017-06-15 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hiv抗原をコードするポックスウイルスベクターおよびその使用方法 |
BR112020000867A2 (pt) * | 2017-07-19 | 2020-07-21 | Janssen Vaccines & Prevention B.V. | mutações da proteína do envelope do hiv estabilizando o trímero |
US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
EP3504225B1 (fr) * | 2017-11-17 | 2024-04-24 | Grifols Diagnostic Solutions Inc. | Nouveaux antigènes protéiques de l'enveloppe protéique du virus de l'immunodéficience humaine exprimés chez les mammifères |
US20220211835A1 (en) * | 2019-04-17 | 2022-07-07 | The Wistar Institute | Replication Deficient Adenoviral Vectors for HIV Vaccine Applications |
WO2020237052A1 (fr) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets suivant un traitement antirétroviral |
AU2020381082B2 (en) | 2019-11-07 | 2022-09-22 | Janssen Vaccines & Prevention B.V. | Protein purification |
CA3182703A1 (fr) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration de vecteurs adenoviraux homologues |
WO2022006095A2 (fr) * | 2020-06-29 | 2022-01-06 | Duke University | Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc |
US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
JP2024509769A (ja) | 2021-02-23 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 三量体安定化hivエンベロープタンパク質変異 |
WO2023242155A1 (fr) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions et procédés pour le diagnostic d'une infection par le vih |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1341245C (fr) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Virus recombinant de la vaccine derive du virus modifie ankara |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
PT1550722E (pt) | 1999-05-17 | 2007-09-25 | Crucell Holland Bv | ''adenovírus humano recombinante do serótipo 35'' |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
CA2384271A1 (fr) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Trimeres stabilises solubles de glycoproteines |
ES2256323T5 (es) | 2000-11-23 | 2016-11-21 | Bavarian Nordic A/S | Variante del virus Vaccinia Ankara Modificado |
CA2785699A1 (fr) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations |
CA2452119C (fr) * | 2001-07-05 | 2013-10-15 | Chiron Corporation | Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations |
CN102409063A (zh) | 2001-12-04 | 2012-04-11 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
CA2478508C (fr) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Vecteurs adenoviraux stables et techniques de propagation de ces vecteurs |
EP1497438B1 (fr) | 2002-04-25 | 2009-10-28 | Crucell Holland B.V. | Moyens et procede de production de vecteurs d'adenovirus |
AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
ES2416629T3 (es) | 2002-12-03 | 2013-08-02 | University Of Massachusetts | Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación |
EP2371380A1 (fr) | 2003-03-28 | 2011-10-05 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA exprimant des gènes enveloppe, gag et pol du vih |
WO2005027840A2 (fr) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Approches combinees pour produire des reponses immunitaires |
WO2005052119A2 (fr) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants de la reponse immunitaire |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
US20070207166A1 (en) * | 2004-04-12 | 2007-09-06 | Genvec, Inc. | Method of Using Adenoviral Vectors to Induce an Immune Response |
EP1766097A4 (fr) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1 |
JP4772045B2 (ja) * | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Cmv/r核酸コンストラクトを含むaidsに対するワクチン |
DK1789438T3 (en) * | 2004-08-27 | 2015-07-20 | Us Government | Recombinant MVA viruses expressing MODIFIED env, gag and pol genes of HIV CLADE A / G, CLADE CLADE B AND C |
US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
EP1917040A4 (fr) | 2005-08-23 | 2012-12-12 | Univ California | Vaccin polyvalent |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
EP2040747A4 (fr) | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | Protéines env vih trimériques solubles stabilisées et leurs utilisations |
EP2073840A4 (fr) | 2006-10-23 | 2010-10-27 | Progenics Pharm Inc | Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci |
WO2008140579A2 (fr) | 2006-11-17 | 2008-11-20 | New York University | Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1 |
EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
WO2010042942A2 (fr) | 2008-10-10 | 2010-04-15 | Children's Medical Center Corporation | Vaccin trimère anti-vih-1 env stabilisé biochimiquement |
EP2358757B1 (fr) * | 2008-11-18 | 2018-09-12 | Beth Israel Deaconess Medical Center | Vaccins antiviraux présentant une immunogénicité cellulaire améliorée |
WO2010085984A1 (fr) | 2009-02-02 | 2010-08-05 | Okairos Ag | Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations |
SG172935A1 (en) | 2009-02-02 | 2011-08-29 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
WO2010096561A1 (fr) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protéines gag du vih/vis de synthèse et leurs utilisations |
CN102711794B (zh) | 2010-01-04 | 2015-11-25 | Kj生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
WO2011092029A1 (fr) | 2010-01-28 | 2011-08-04 | Bavarian Nordic A/S | Mutants du virus de la vaccine comportant les principales délétions génomiques du virus de la vaccine ankara modifiée |
EP4226935A3 (fr) | 2010-08-31 | 2023-09-06 | Theraclone Sciences, Inc. | Anticorps neutralisant le virus de l'immunodéficience humaine (vih) |
BR112013014712B1 (pt) | 2010-12-14 | 2021-03-02 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | primeiro e segundo vetores de adenovírus recombinantes |
WO2012149038A1 (fr) * | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci |
US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
EP2568289A3 (fr) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants |
WO2013040766A1 (fr) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Procédé et vaccin pouvant induire une réponse immunitaire à large spectre contre le vih |
WO2013055908A1 (fr) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | Mini boucle v3 de gp120 du vih-1 et ses utilisations |
US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
MX2015008815A (es) | 2013-01-07 | 2016-10-26 | Beth Israel Deaconess Medical Ct Inc | Vacunas de trimero del envolvente (env) del virus de la inmunodeficiencia humana (vih) estabilizadas y metodos de usarlas. |
WO2014124301A1 (fr) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Nanostructures protéiques à auto-assemblage |
US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
WO2015048770A2 (fr) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Traitements par anticorps pour le virus de l'immunodéficience humaine (vih) |
EP3666790A1 (fr) * | 2013-10-04 | 2020-06-17 | Beth Israel Deaconess Medical Center, Inc. | Caccins de trimères d'enveloppe (env) de clade c du virus de l'immunodéficience humaine (vih) stabilisés et procédés d'utilisation de ceux-ci |
US9750801B2 (en) * | 2014-02-28 | 2017-09-05 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
EP3189067B1 (fr) | 2014-09-04 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Protéines de l'enveloppe du vih-1 et leur utilisation |
AP2017009846A0 (en) | 2014-09-26 | 2017-03-31 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
WO2016146844A1 (fr) * | 2015-03-18 | 2016-09-22 | Janssen Vaccines & Prevention B.V. | Dosages pour systèmes d'expression de recombinaison |
MD3390430T2 (ro) | 2015-12-15 | 2019-12-31 | Janssen Vaccines & Prevention Bv | Antigenele virusului imunodeficienței umane, vectori, compoziții și metode de utilizare ale acestora |
MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
EA201990715A1 (ru) | 2016-09-15 | 2019-08-30 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизирующие тример мутации белка оболочки hiv |
DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro unknown
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro unknown
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/fr not_active Withdrawn
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 MX MX2018007198A patent/MX2018007198A/es unknown
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh active
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/fr unknown
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 KR KR1020187016460A patent/KR20180086207A/ko not_active Application Discontinuation
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh active
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active Search and Examination
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/fr active Application Filing
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/fr active Active
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 CA CA3008542A patent/CA3008542C/fr active Active
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/fr active Active
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja active Active
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-10-21 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47522B1 (fr) | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation | |
MA40765B1 (fr) | Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine | |
PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
MX2018004544A (es) | Composiciones y métodos para los neoepítopos de cáncer viral. | |
MA52645B1 (fr) | Vaccins contre le virus respiratoire | |
MA43124A (fr) | Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse | |
MX2017015462A (es) | Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas. | |
PH12017501165A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
MX2018003533A (es) | Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso. | |
EA202191862A3 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения |